Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Drops By 17.5%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 4,540,000 shares, a drop of 17.5% from the December 15th total of 5,500,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 3.5 days.

Zentalis Pharmaceuticals Trading Up 8.0 %

NASDAQ ZNTL opened at $2.85 on Thursday. Zentalis Pharmaceuticals has a fifty-two week low of $2.41 and a fifty-two week high of $18.07. The stock has a 50 day simple moving average of $3.29 and a two-hundred day simple moving average of $3.42.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, sell-side analysts expect that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Large investors have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals in the third quarter worth about $37,000. Paloma Partners Management Co bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Aigen Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $41,000. Capstone Investment Advisors LLC bought a new position in Zentalis Pharmaceuticals in the third quarter worth $48,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Guggenheim reduced their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.